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Background: Understanding the etiologic organism, antimicrobial resistance mechanisms, and
transmission of multidrug-resistant tuberculosis (MDR-TB) can be of great value in optimizing
strategies to control and prevent its development and transmission.
Methods: One hundred and fifty-fiveMycobacterium tuberculosis complex isolates from patients
with pulmonary tuberculosis (TB) in Cairo, Egypt were studied. In vitro drug susceptibility testing
against rifampin (RIF), isoniazid (INH), streptomycin (SM), ethambutol (EMB), and pyrazinamide
(PZA) was performed. Resistance was studied by the standard agar proportion method. Single
strand conformation polymorphism (SSCP) and DNA sequence analysis were used to detect
mutations in the genes that encode resistance to rpoB, katG, rpsL, and embB.
Results: Among 155 consecutive M. tuberculosis isolates, 25 (16.1%) were MDR-TB; 13 of these
were from newly diagnosed untreated cases, 12 were from re-treated cases, and none of the MDR-
TB isolates had matching IS6110 fingerprints. Among the MDR-TB isolates, rpoB mutations were
found in 76% of RIF-resistant isolates, katG mutations were found in 47.1% of INH-resistant
isolates, rpsL mutations were found in 55.6% of SM-resistant isolates, and embB mutations were
found in 36.4% of EMB-resistant isolates.
Conclusions: No major differences were found in the frequencies of mutations or types of amino
acid substitution between newly diagnosed untreated cases and re-treated cases. The high
prevalence of MDR-TB at this hospital underscores the need for continuous monitoring of strains
and antimicrobial resistance.
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Tuberculosis (TB), especially multidrug-resistant TB (MDR-
TB), is a global problem, and a prevalence of MDR-TB as high
as 26.8% has recently been reported.1—3 MDR-TB strains are
generally defined as resistant to at least isoniazid (INH) and
rifampin (RIF). These strains have been described worldwide,
and their existence poses a serious threat to TB control
programs in many countries. Understanding the etiologic
organism, antimicrobial resistance mechanisms, and trans-
mission of MDR-TB can be of great value in optimizing stra-
tegies to control and prevent its development and
transmission.4
The frequency of resistance to multiple drugs varies
geographically, and acquired (secondary) resistance is more
common than primary resistance. High rates of acquired
MDR-TB have been reported in Nepal (48.0%), India
(33.8%), and in New York City (approximately 30%).5 Although
studies have shown an overall decrease in the number of
MDR-TB cases reported in New York City and throughout the
USA, the number of states reporting these organisms has
actually increased substantially since the early 1990s.5 The
treatment of patients with MDR-TB is substantially more
difficult than the treatment of individuals infected with
drug-susceptible strains.
El-Gazzar et al. found that among 400 newly diagnosed
patients with active pulmonary TB in urban and rural areas of
Qualiobia governorate, Egypt, the prevalence of primary
resistance to streptomycin (SM) was 32.3%, to INH was 25%,
to ethambutol (EMB) was 17.5%, to RIF was 12.5%, and to
pyrazinamide (PZA) was 7.5%.6 The prevalence of primary
resistance to one drug was 40%, to two drugs was 20%, and to
three drugs was 5%, but no resistance was found to four or
five drugs.6 Abbadi et al. studied 25 Mycobacterium tuber-
culosis isolates from Assiut region in Egypt, and found 11
(44%) MDR isolates, but these patients had undergone at
least one year of prior TB therapy.7 Theoretically, MDR-TB
strains could arise as a consequence of sequential accumu-
lation of mutations conferring resistance to single thera-
peutic agents, by a single-step process such as acquisition of
an MDR genetic element, or through a mutation that alters
cell wall structure affecting drug uptake.8 A well-documen-
ted example of how MDR-TB strains arise has been provided
by the analysis of the evolution of two closely related
subclones in New York City, arbitrarily designated as W
and W1.9 Automated DNA sequencing of representative
organisms defined the series of distinctmutations conferring
resistance to RIF, INH, SM, EMB, and PZA. For example, a
His526Tyr amino acid substitution was responsible for con-
ferring RIF resistance and a Ser315Thr substitution was
responsible for INH resistance.10 These MDR isolates arise
because random mutations in genes that encode targets for
the individual antimicrobial agents are selected by sub-
therapeutic drug levels that can occur due to processes such
as treatment errors, poor adherence to treatment protocols,
or other factors.11
Several methods such as direct sequencing of PCR pro-
ducts, single-strand conformation polymorphism (SSCP) ana-
lysis, the base pair-mismatch assay, the reverse
hybridization-based line probe assay, and other strategies,
are designed to exploit the observation that specific muta-
tions that are found in resistant strains are absent in suscep-tible organisms. The fact that natural populations of drug-
susceptible M. tuberculosis complex isolates recovered glob-
ally have remarkably few polymorphisms in structural genes,
greatly simplifies interpretation of these assays. The
restricted allelic variation in structural genes means that
virtually all susceptible organisms will have the same wild-
type allele of the target gene. Hence, one generally needs to
differentiate between a single wild-type sequence and
mutant sequences. Among the many techniques used to
identify drug resistance-associated mutations, automated
DNA sequencing of PCR products has been the most widely
applied. One important advantage of sequence-based
approaches is that the resulting data are virtually unambig-
uous because a resistance-associated mutation is either pre-
sent or absent. Telenti et al. similarly demonstrated good
performance of SSCP-based interrogation of target
sequences. Missense mutations and short deletions in one
region of the gene that encodes the RNA polymerase beta
subunit (rpoB) cause RIF resistance in Escherichia coli.12 This
insight led to the characterization of rpoB in M. tuberculo-
sis,13 and to the identification of a wide variety of mutations
conferring RIF resistance in this species as well.12
All genotypic drug resistance strategies suffer from the
fact that the molecular mechanisms explaining the resis-
tance of anti-tuberculosis agents are not fully understood.14
Hence identification of resistance-associated mutations is
clinically informative, whereas lack of a mutation in the
target sequence must be interpreted with considerable cau-
tion. In Egypt, there is no database for MDR-TB. We inves-
tigated mutations associated with anti-tuberculosis drug
resistance among strains of M. tuberculosis isolated from
patients at the Abbasia Chest Hospital, Cairo, Egypt, a major
reference hospital with 900 beds and the largest case load of
TB patients in Egypt. This hospital is considered to be a
reference hospital for pulmonary diseases throughout the
Middle East.
Materials and methods
Bacterial isolates and patient analysis
One hundred and fifty-five M. tuberculosis isolates were
included in this study. They were isolated from 371 successive
sputum specimens collected from symptomatic patients with
pulmonary tuberculosis at Abbasia Chest Hospital, Cairo,
Egypt. Two hundred and fifty-three isolates were from acute
untreated cases and 118 were from chronic previously trea-
ted cases.
A PCR restriction fragment length polymorphism (RFLP)
assay to identify a polymorphism in oxyR was performed to
distinguishMycobacterium bovis andM. bovis BCG from other
members of the M. tuberculosis complex.15
Anti-tuberculosis drug susceptibility testing
Drug susceptibility testing was performed by a modified
proportion method as described by Kent and Kubica using
Middlebrook and Cohn 7H10 agar plates containing the fol-
lowing concentrations of each of five drugs: RIF (1.0 mg/ml),
INH (0.2, 1.0, and 5.0 mg/ml), SM (2.0 and 10.0 mg/ml), EMB
(5.0 mg/ml), and PZA (25.0 mg/ml).16
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Strain typing was performed at the Mycobacteriology Labora-
tory Branch, Centers for Disease Control and Prevention,
Atlanta, Georgia, USA, using a standardized RFLP method.
A chemiluminescence-labeled amplification product of the
insertion element IS6110 was used as a genomic probe.17
PCR-based single-strand conformational
polymorphism (SSCP) analysis
Crude lysates containing genomic DNA for use as templates
for PCR were prepared from Middlebrook 7H9 broth cultures
by disruption of cells with siliconized glass beads as pre-
viously described.18 Regions of rpoB, katG, rpsL, and embB
were PCR-amplified using previously described conditions
and oligonucleotide primers (Table 1).7,19,20
The PCR products were analyzed for mutations using non-
radioactive SSCPelectrophoresis. Briefly, SSCP was performed
byheatingamixture consistingof 5 ml (approximately 50ng) of
PCR product and 15 ml of deionized formamide at 95 8C for
4 min, followed by electrophoresis in 4—20% gradient acryla-
mide gels (Invitrogen Corp., Carlsbad, CA, USA) at 300 V for
1.75 h in Tris-borate-EDTA (TBE) buffer maintained at 13 8C.20
DNA sequencing and DNA sequence analysis
Sequencing of both strands of the PCR product was performed
on an ABI373 sequencing instrument according to the proto-
col supplied by the manufacturer using the Big DyeTM Termi-
nator Cycle Sequencing Ready Reaction kit (PE Applied
Biosystems, Foster City, CA, USA).
Results
Anti-tuberculosis drug susceptibility results
Among the 155 cases, 121 (78.1%) were untreated newly
diagnosed cases and 34 (21.9%) were re-treated cases. Drug
susceptibility testing using the standard proportion method
revealed that 79 (51.0%) isolates were susceptible in vitro to
all anti-tuberculosis drugs tested; 62 of these isolates were
from untreated patients and 17 isolates were from previously
treated patients. Thirty-four (21.9%) isolates were mono-
resistant to RIF, INH, SM, EMB, or PZA, and 33 of these isolates
were from untreated patients. Twenty-one (13.6%) were
mono-resistant to SM, three (1.9%) to RIF, six (3.9%) to
INH, and two each (1.3%) to EMB and PZA. Twenty-five
(16.1%) isolates were MDR (at least to RIF and INH), and 12
of these were from previously treated patients. These 12 MDRTable 1 Genome regions examined for mutations.
Drug Gene Nucleotide Codons
RIF rpoB 2336—2463 500—541
INH katG 725—1047 243—349
EMB embB 7771—8047 270—362
SM rpsL 4—310 2—103
RIF, rifampin; INH, isoniazid; EMB, ethambutol; SM, streptomycin.isolates accounted for 35.3% of the 34 isolates from pre-
viously treated patients as compared to 10.7% (13 MDR
isolates among 121) isolates from previously untreated
patients (Table 2). Seventeen isolates that were resistant
to multiple drugs but not to both INH and RIF, included five
isolates (3.2%) that were resistant to SM and RIF, two (1.3%) to
INH and EMB, seven (4.5%) to INH and SM, one (0.7%) to SM,
RIF, and EMB, one (0.7%) to PZA, SM, RIF, and EMB, and one
(0.7%) to PZA and SM. Thirteen of these isolates were from
previously untreated patients. All INH-resistant isolates were
resistant to either 0.2 mg/ml or 1.0 mg/ml, and none was
resistant to 5 mg/ml, INH. The six PZA-resistant isolates were
tested by oxyR PCR-RFLP and none was identified asM. bovis.
Strain typing
There were no strain clusters among the 25 MDR-TB isolates
as determined using IS6110 RFLP analysis. Twenty-five unique
banding patterns with from 5 to16 copies of IS6110 were
observed.
Mutations
The gene regions shown in Table 1 were examined using DNA
sequence analysis and SSCP electrophoresis, and 41 muta-
tions were found among the 25 MDR-TB strains (Table 3). The
rpoB resistance determinant region (RRDR) was examined in
25 RIF-resistant MDR isolates, katG in 17 INH-resistant MDR
isolates, rpsL in 18 SM-resistant MDR isolates, and embB in 11
EMB-resistant MDR isolates (Table 3). Amino acid substitu-
tions in rpoB were found in 19 isolates (76%) with the most
common being Ser531Leu, which was found in 13 of the 19
rpoB mutants. Amino acid substitutions in katG were identi-
fied in eight of 17 isolates examined (47.1%) all of which
involved the katG315 codon. All of the 17 isolates examined
were resistant to 1 mg/ml INH, but were susceptible to 5 mg/
ml. Four Lys43Arg and six Lys88Arg substitutions were iden-
tified in 10 of 18 (55.6%) SM-resistant isolates, all of which
were resistant to 10 mg/ml SM. No rpsLmutations were found
among eight isolates with low-level SM resistance (2 mg/ml<
minimum inhibitory concentration (MIC) < 10 mg/ml). Muta-
tions in embB that cause substitutions at codon 306 were
found in four of 11 EMB-resistant isolates (36.4%). The SSCP
band patterns of the nine mutations shown in Table 3 were
different compared with wild-type SSCP patterns (Figure 1).
Discussion
Patients in this study were all from Abbasia Chest Hospital,
which serves patients from all regions of Cairo as well asSize (bp) Reference
128 Miller et al. (13); Cooksey et al. (20)
321 Abbadi et al. (7)
276 Sreevatsan et al. (32)
306 Honore and Cole (37)
Table 2 Antimicrobial resistance patterns among 155 Mycobacterium tuberculosis isolates from Abbasia Chest Hospital, Cairo,
Egypt.
Resistance patterns Previous treatment
No Yes Total
PZA SM RIF INH EMB n % n % n %
Fully susceptible (n = 79)      62 51.24 17 50 79 50.97
SDR (n = 34)  +    20 16.53 1 2.94 21 13.55
  +   3 2.48 0 0 3 1.94
   +  6 4.96 0 0 6 3.87
    + 2 1.65 0 0 2 1.29
+     2 1.65 0 0 2 1.29
MDR (n = 25)   + +  4 3.31 1 2.94 5 3.23
 + + +  1 0.83 2 5.88 3 1.94
+ + + +  0 0 1 2.94 1 0.65
  + + + 1 0.83 1 2.94 2 1.29
 + + + + 6 4.96 7 20.59 13 8.39
+ + + + + 1 0.83 0 0 1 0.65
ODR (n = 17)  + +   3 2.48 2 5.88 5 3.23
   + + 1 0.83 1 2.94 2 1.29
 +  +  6 4.96 1 2.94 7 4.52
 + +  + 1 0.83 0 0 1 0.65
+ + +  + 1 0.83 0 0 1 0.65
+ +    1 0.83 0 0 1 0.65
Total 121 100 34 100 155 100
+, resistant; , susceptible; PZA, pyrazinamide; SM, streptomycin; RIF, rifampin; INH, isoniazid; EMB, ethambutol; SDR, single drug
resistance; MDR, multidrug resistance; ODR, other drug resistance.
676 S.H. Abbadi et al.other nearby governorates in Lower Egypt. This makes our
data a likely representation of the genetic makeup of strains
throughout this region of Egypt. All of the 155 cases in our
study were directly observed therapy (DOT) patients. This
and other treatment practices at Abbasia that could influ-
ence antimicrobial resistance do not differ from other
regions in Egypt.
The patients included 121 who had never received anti-
tuberculosis therapy and for whom primary resistance is more
likely, as well as 34 who had received anti-tuberculosis
therapy and for whom secondary resistance is more likely.
Multidrug resistance (resistance to at least RIF and INH) wasTable 3 Mutations among 25 multidrug-resistant Mycobacterium
Drug Gene (number tested) Number of s




Isoniazid katG (17) 7
1
9
Streptomycin rpsL (18) 4
6
8
Ethambutol embB (11) 2
2
7
wt, wild type.found in 25 isolates (16.1%), and additional resistance to SM,
EMB, and PZA was found in 18, 16, and two isolates, respec-
tively. Thirteen MDR isolates (10.7%) were from newly diag-
nosed untreated cases and 12 (35.3%) were from re-treated
cases. We found single drug resistance in 34 of 155 isolates
(21.9%), which is less than in a previous study of TB in Egypt in
which resistance to a single drug was found in 18 of 50 isolates
(36%).21 We also observed lower percentages of isolates that
were resistant to two drugs or three drugs than in the
previous study in which 13 isolates (26%) were resistant to
two drugs and two isolates (4%) were resistant to three drugs.
However, none of the 50 isolates in the previous study wastuberculosis strains.














Figure 1 Single strand conformation polymorphism patterns of
multidrug-resistant Mycobacterium tuberculosis isolates from
Abbasia Hospital, Cairo, Egypt. PCR products (Table 1) were
denatured and electrophoresed in 4—20% gradient acrylamide
gels for 1.75 h, 300 V, 13 8C. Lane 1, rpoB mutant (Asp516Val);
lane 2, rpoB mutant (Ser531Leu); lane 3, rpoB mutant (His526-
Tyr); lane 4, rpoBwt; lane 5, katG mutant (Ser315Thr); lane 6,
katG mutant (Ser315Arg); lane 7, katGwt; lane 8, rpsL mutant
(Lys43Arg); lane 9, rpsLmutant (Lys88Arg); lane 10, rpsLwt; lane
11, embB mutant (Met306Ile); lane 12, embB mutant (Met306-
Val); lane 13, embBwt; lane S, 100-bp size standard.
Mutations associated with anti-TB drug resistance 677resistant to four drugs, even though primary resistance to SM
was reported in 22 isolates (44%), to INH in 16 isolates (32%),
and to RIF in nine isolates (18%).21
The overall prevalence of resistance among our isolates
was lower than that reported in 1996 by the Egyptian
National Tuberculosis Program (ENTP) for pulmonary iso-
lates.22 Among 250 isolates tested in the ENTP study,
55.2% were resistant, compared to 49.0% of our isolates.
Resistance to INH, however, was more common among our
isolates (25.8%) than among the ENTP isolates (6.4%).
We identified rpoBmutations in 76% of the 25 RIF-resistant
isolates, which is consistent with the results of Abbadi et al.,
who found mutations in 73% of RIF-resistant isolates.7 How-
ever, previous studies have reported higher correlations of
rpoB mutations with RIF resistance, and this inconsistency
may warrant additional investigation.8,23 We found three
distinct rpoB mutations among 19 MDR isolates, all of which
were reported previously among Egyptian isolates, and glob-
ally as well.7,23,24
The role of katG in mediating susceptibility to INH has
been established.25,26 Investigators have reported that many
(approximately 50—60%) INH-resistant isolates have missense
mutations or small deletions or insertions in katG that are not
present among INH-susceptible control strains.27 Amino acid
substitutions in the katG315 codon are more abundant than
other mutations among INH-resistant strains.28 Among the 17
MDR-TB isolates we studied, eight (47.1%) had mutations at
codon 315 in katG; seven (87.5%) had Ser315Thr (AGC!ACC)
substitutions, one (12.5%) had a Ser315Arg (AGC!AGA) sub-
stitution, and nine had no detectable mutations in the region
of katG we studied. Our results agree with the study by
Abbadi et al. who found that 40% of the INH-resistant isolates
had mutations in katG (all Ser315Thr).7 Gomaa identifiedkatG mutations in 77.8% of INH-resistant isolates.23 Musser
et al. studied INH-resistant strains from global sources, and
identified a katG315 missense substitution in 58% of epide-
miologically associated isolates.28 Also, Haas et al. reported
that 68% of INH-resistant strains from Africa had codon 315
missense changes (most often Ser315Thr substitutions), and
Dobner et al. found that 26 of 27 (96%) INH-resistant isolates
from Germany and Sierra Leone also had codon 315 muta-
tions.29,30 Statistically, the most common amino acid sub-
stitution is AGC (Ser)!ACC (Thr), but substitution of Ser with
Arg, Asn, Ile, or Gly has also been reported.26 It is likely,
however, that mutations were present in other genes that we
did not evaluate (e.g., inhA, and other katG regions).31 In this
study INH-resistant strains with MICs between 0.2 and 1 mg/
ml had katG315 amino acid substitutions. Previous reports
have failed to identify amino acid substitution strains with
low level INH MICs (1—2 mg/ml).31
The 25 MDR-TB isolates included 18 SM-resistant isolates
and two distinct mutations were identified in ten of these
(55.6%). Four of these (40%) had mutations at codon 43
(Lys!Arg; AAG!AGG), and six (60%) had mutations at codon
88 (Lys!Arg; AAG!AGG). Our findings are in agreement with
previous studies of SM-resistant strains by Sreevatsan et al.
and by Abbadi et al. who identified that most missense
mutations occur at either codon 43 or codon 88 of rpsL.7,32
Mutations in rpsL were detected in 10 isolates with high-
level SM resistance (MIC > 10 mg/ml), but not in eight iso-
lates with low-level SM resistance (2.0 < MIC < 10 mg/ml).
This finding agrees with Cooksey et al. who analyzed 45 SM-
resistant isolates for phenotypic resistance and mutations,
and found that all 24 high-level (MIC > 500 mg/ml) resistant
isolates had Lys43Arg changes in rpsL and that among the low
level (MIC < 10 mg/ml) SM-resistant isolates, one had a C!G
substitution at position 903 of the 16S rRNA gene (rrs) and
none had rpsL mutations.33
EMB resistance is most often found in association with
mutations at codon 306 of embB that cause Met to Ile or Met
to Val substitutions.34 In our study, 16 of the 25 MDR-TB were
EMB-resistant, and two distinct mutations in embB codon 306
were found in four isolates (36.4%). Two isolates each had Met
to Ile or Met to Val amino acid substitutions. These mutations
have previously been reported by Telenti et al., Sreevatsan
et al., and by Abbadi et al.7,32,35
We evaluated the 155 study isolates for in vitro suscept-
ibility to PZA even though this test is not routinely performed
in Egyptian mycobacteriology laboratories and PZA is not
routinely used in clinical practice in Egypt. Six isolates
(3.9%) were PZA-resistant; two of these were resistant only
to PZA, two were MDR-TB, and all six were determined to be
M. tuberculosis complex species other than M. bovis using
oxyR PCR-RFLP. Genotypic susceptibility testing for the six
PZA-resistant isolates was not done since the array of muta-
tions in pncA is so diverse and there are no convenient
genotypic assays yet available for screening for PZA resis-
tance.36
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